References
Abassi, Z.A., Tate, J.E., Golomb, E., and Keiser, H.R. (1992). Role of
neutral endopeptidase in the metabolism of endothelin. Hypertension20 : 89–95.
Aird, W.C. (2003). The role of the endothelium in severe sepsis and
multiple organ dysfunction syndrome. Blood 101 : 3765–3777.
Alexander, S.P.H., Christopoulos, A., Davenport, A.P., Kelly, E.,
Mathie, A., Peters, J.A., et al. (2019). THE CONCISE GUIDE TO
PHARMACOLOGY 2019/20: G protein-coupled receptors. Br. J. Pharmacol.176 : S21–S141.
Amara, N., Goven, D., Prost, F., Muloway, R., Crestani, B., and
Boczkowski, J. (2010). NOX4/NADPH oxidase expression is increased in
pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis
and mediates TGFbeta1-induced fibroblast differentiation into
myofibroblasts. Thorax 65 : 733–738.
Annane, P.D., Bellissant, P.E., and Cavaillon, J.M. (2005). Septic
shock. In Lancet, pp 63–78.
Avula, A., Nalleballe, K., Narula, N., Sapozhnikov, S., Dandu, V., Toom,
S., et al. (2020). COVID-19 presenting as stroke. Brain. Behav. Immun.
Ayoub, S., and Melzig, M.F. (2008). Influence of Selected Natural
Products on Neutral Endopeptidase Activity and β-Amyloid Production in
SK-N-SH Cells. Pharm. Biol. 46 : 425–432.
Azevedo, M.F., Faucz, F.R., Bimpaki, E., Horvath, A., Levy, I.,
Alexandre, R.B. de, et al. (2014). Clinical and molecular genetics of
the phosphodiesterases (PDEs). Endocr. Rev. 35 : 195–233.
Barnette, M.S. (1999). Phosphodiesterase 4 (PDE4) inhibitors in asthma
and chronic obstructive pulmonary disease (COPD). Prog. Drug Res.53 : 193–229.
Bateman, E.D., Goehring, U.-M., Richard, F., and Watz, H. (2016).
Roflumilast combined with montelukast versus montelukast alone as add-on
treatment in patients with moderate-to-severe asthma. J. Allergy Clin.
Immunol. 138 : 142–149.
Bateman, E.D., Izquierdo, J.L., Harnest, U., Hofbauer, P., Magyar, P.,
Schmid-Wirlitsch, C., et al. (2006). Efficacy and safety of roflumilast
in the treatment of asthma. Ann. Allergy, Asthma Immunol. 96 :
679–686.
Baye, J. (2012). Roflumilast (daliresp): a novel phosphodiesterase-4
inhibitor for the treatment of severe chronic obstructive pulmonary
disease. P T 37 : 149–61.
Belen-Apak, F.B., and Sarıalioğlu, F. (2020). Pulmonary intravascular
coagulation in COVID-19: possible pathogenesis and recommendations on
anticoagulant/thrombolytic therapy. J. Thromb. Thrombolysis May :
1–3.
Borson, D.B. (1991). Roles of neutral endopeptidase in airways. Am. J.
Physiol. - Lung Cell. Mol. Physiol. 260 : L212-25.
Borson, D.B., Brokaw, J.J., Sekizawa, K., McDonald, D.M., and Nadel,
J.A. (1989). Neutral endopeptidase and neurogenic inflammation in rats
with respiratory infections. J. Appl. Physiol. 66 : 2653–2658.
Borson, D.B., and Gruenert, D.C. (1991). Glucocorticoids induce neutral
endopeptidase in transformed human tracheal epithelial cells. Am. J.
Physiol. - Lung Cell. Mol. Physiol. 260 : L83-9.
Boswell-Smith, V., Cazzola, M., and Page, C.P. (2006). Are
phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin.
Immunol. 117 : 1237–1243.
Bridgewood, C., Damiani, G., Sharif, K., and Quartuccio, L. (2020).
Rationale for use of PDE4 inhibition for severe inflammation in COVID-19
Pneumonia. 323 : 1824–1836.
Burgess, J.K., Oliver, B.G.G., Poniris, M.H., Ge, Q., Boustany, S., Cox,
N., et al. (2006). A phosphodiesterase 4 inhibitor inhibits matrix
protein deposition in airways in vitro. J. Allergy Clin. Immunol.118 : 649–657.
Cai, B., Cai, J., Luo, Y., Chen, C., and Zhang, S. (2015). The specific
roles of JAK/STAT signaling pathway in sepsis. Inflammation 38 :
1599–1608.
Campochiaro, C., Della-Torre, E., Cavalli, G., Luca, G. De, Ripa, M.,
Boffini, N., et al. (2020). Efficacy and safety of tocilizumab in severe
COVID-19 patients: a single-centre retrospective cohort study. Eur. J.
Intern. Med. 76 : 43–49.
Carpenter, T.C., and Stenmark, K.R. (2001). Hypoxia decreases lung
neprilysin expression and increases pulmonary vascular leak. Am. J.
Physiol. - Lung Cell. Mol. Physiol. 281 : L941-48.
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., and Napoli, R. Di
(2020). Features, Evaluation and Treatment Coronavirus (COVID-19)
(StatPearls Publishing).
Chang, X., Hu, L.F., Ma, X.J., Yin, J., Liu, X.Y., and Li, J.B. (2019).
Influence of roflumilast on sepsis mice through the JAK/STAT signaling
pathway. Eur. Rev. Med. Pharmacol. Sci. 23 : 1335–1341.
Chang, X., Rong, C., Chen, Y., Yang, C., Hu, Q., Mo, Y., et al. (2015).
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in
Alzheimer’s disease model mice by upregulating neprilysin expression.
Exp. Cell Res. 334 : 136–145.
Chapman, R.W., House, A., Jones, H., Richard, J., Celly, C., Prelusky,
D., et al. (2007). Effect of inhaled roflumilast on the prevention and
resolution of allergen-induced late phase airflow obstruction in Brown
Norway rats. Eur. J. Pharmacol. 571 : 215–221.
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., et al. (2018).
Inflammatory responses and inflammation-associated diseases in organs.
Oncotarget 9 : 7204–7218.
Connelly, J.C., Skidgel, R.A., Schulz, W.W., Johnson, A.R., and Erdös,
E.G. (1985). Neutral endopeptidase 24.11 in human neutrophils: Cleavage
of chemotactic peptide. Proc. Natl. Acad. Sci. U. S. A. 82 :
8737–8741.
Cox, M.J., Loman, N., Bogaert, D., and O’Grady, J. (2020).
Co-infections: potentially lethal and unexplored in COVID-19. The Lancet
Microbe 1 : e11.
Crowther, M.A. (2001). Continuing Challenges of Sepsis Research. JAMA286 : 1894.
CSSE, J.H. (2020). Index @ Gisanddata.Maps.Arcgis.Com.